The radiomics nomogram predicts the prognosis of pancreatic cancer patients with hepatic metastasis after chemoimmunotherapy

Abstract

Objective To construct a prognostic model based on MR features and clinical data to evaluate the progression free survival (PFS), overall survival (OS) and objective response rate (ORR) of pancreatic cancer patients with hepatic metastases who received chemoimmunotherapy. Methods 105 pancreatic cancer patients with hepatic metastases who received chemoimmunotherapy were assigned to the training set (n = 52), validation set (n = 22), and testing set (n = 31). Multi-lesion volume of interest were delineated, multi-sequence radiomics features were extracted, and the radiomics models for predicting PFS, OS and ORR were constructed, respectively. Clinical variables were extracted, and the clinical models for predicting PFS, OS and ORR were constructed, respectively. The nomogram was jointly constructed by radiomics model and clinical model. Result The ORR exhibits no significant correlation with either PFS or OS. The area under the curve (AUC) of nomogram for predicting 6-month PFS reached 0.847 (0.737–0.957), 0.786 (0.566–1.000) and 0.864 (0.735–0.994) in the training set, validation set and testing set, respectively. The AUC of nomogram for predicting 1-year OS reached 0.770 (0.635–0.906), 0.743 (0.479–1.000) and 0.818 (0.630–1.000), respectively. The AUC of nomogram for predicting ORR reached 0.914 (0.828–1.00), 0.938 (0.840–1.00) and 0.846 (0.689–1.00), respectively. Conclusion The prognostic models based on MR imaging features and clinical data are effective in predicting the PFS, OS and ORR of chemoimmunotherapy in pancreatic cancer patients with hepatic metastasis, and can be used to evaluate the prognosis of patients.

Radiomics in Pancreatic Cancer: Present and Future

“…2 A recent study demonstrated that prognostic radiomics models, incorporating MRI features and clinical data, are effective in predicting progression-free survival, overall survival, and objective response rate in PC patients with hepatic metastasis undergoing chemoimmunotherapy. 17 These models hold promise for evaluating patient prognosis.…”